Tag:
NewLink Genetics
Latest Headlines
Latest Headlines
Vax-chemo combo offers some hope in pancreatic cancer
Pancreatic cancer is hard to treat, but adding a cancer vaccine to standard chemotherapy could boost survival.
Key to IPO success: recruiting 'insiders' who will buy into the offering
The Scientist takes a crack at covering the few courageous--or is it foolhardy?--biotech companies willing to go public these days. Steven Burrill notes that there's no appetite for risk, echoing...
Cancer vax developer NewLink Genetics' IPO nets $43.4M
It's worth letting out a "hooray" when a biotech does an initial public offering. NewLink Genetics , a cancer vaccine developer, made its public debut today, raising about $43.4 million through the
NewLink looks to IPO for $66M to back cancer vaccine
An Iowa-based biotech named NewLink Genetics is gambling that its late-stage therapeutic cancer vaccine can light a fire under investors as it sets out to garner up to $66 million from an IPO.
NewLink nails $7.5M round
NewLink Genetics in Ames, Iowa, has grabbed $7.5 million in a Series D financing designed to accelerate the clinical development of its therapeutic cancer products. The financing involved additional
